Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 7/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.45 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 6/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28337313 | 0.86 | NOD1 (0.43) | SIRT6SIRT1TLR2GNAI3GNAO1 | |
| SCHEMBL369214 | 0.85 | SIRT1 (0.50) | SIRT6SIRT1TLR2GNAI3GNAO1 | |
| SCHEMBL12534427 | 0.81 | ANPEP (0.41) | SIRT6SIRT1TLR2GNAI3GNAO1 | |
| SCHEMBL28966742 | 0.80 | DGKA (0.46) | NOD1 | |
| SCHEMBL31656070 | 0.80 | DGKA (0.46) | NOD1 | |
| SCHEMBL368473 | 0.80 | SIRT1 (0.51) | SIRT6SIRT1TLR2GNAI3GNAO1 | |
| SCHEMBL2120818 | 0.80 | NOD1 (0.44) | SIRT6SIRT1TLR2GNAI3GNAO1 | |
| SCHEMBL8821920 | 0.78 | NOD1 (0.65) | SIRT6SIRT1TLR2NOD1SLC6A5 | |
| SCHEMBL13028128 | 0.78 | NOD1 (0.62) | SIRT6SIRT1TLR2NOD1SLC6A5 | |
| SCHEMBL25542968 | 0.78 | NOD1 (0.65) | SIRT6SIRT1TLR2NOD1SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545637-B2 | Extrahepatic targeted cationic lipid compound with high efficiency and low toxicity and its composition | BEIJING YOUCARE KECHUANG PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2026-02-10 | — | — | US | disclosed |
| EP-4663624-A1 | EXTRAHEPATIC TARGETED HIGH-EFFICIENCY AND LOW-TOXICITY CATIONIC LIPID COMPOUND AND COMPOSITION THEREOF | Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. (CN) | 2025-12-17 | — | — | EP | disclosed |
| US-20250109092-A1 | EXTRAHEPATIC TARGETED CATIONIC LIPID COMPOUND WITH HIGH EFFICIENCY AND LOW TOXICITY AND ITS COMPOSITION | Beijing Youcarekechuang Pharmaceutical Technology Co., Ltd. (CN) | 2025-04-03 | — | — | US | disclosed |
| WO-2024164426-A1 | EXTRAHEPATIC TARGETED HIGH-EFFICIENCY AND LOW-TOXICITY CATIONIC LIPID COMPOUND AND COMPOSITION THEREOF | 北京悦康科创医药科技股份有限公司 | 2024-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545637-B2 | Extrahepatic targeted cationic lipid compound with high efficiency and low toxicity and its composition | SLC10A1, SLC10A2, LIPC | SIRT6 3816/4885SIRT1 3095/4885TLR2 594/4885 |
| US-20250109092-A1 | EXTRAHEPATIC TARGETED CATIONIC LIPID COMPOUND WITH HIGH EFFICIENCY AND LOW TOXICITY AND ITS COMPOSITION | SLC10A1, LIPC, NPC1L1 | SIRT6 2849/4885SIRT1 2874/4885TLR2 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.